Loading
A phase 3 trial of Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig in biliary tract cancer, run by AstraZeneca, now recruiting.
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer is a phase 3 interventional study registered as NCT06467357 by AstraZeneca, with 620 participants planned, started 2024-08-12 and due to reach its primary completion in 2028-06-12. Interventions recorded: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig.
Shares Durvalumab, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Platinum agents and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Rilvegostomig, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Platinum agents and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.